Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given an average rating of “Moderate Buy” by the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $78.00.

Several equities research analysts have weighed in on VERA shares. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 22,951 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the sale, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. This represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 59,951 shares of company stock valued at $2,392,387 over the last three months. Insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the period. Optimize Financial Inc raised its position in shares of Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after acquiring an additional 256 shares during the period. Virtus Investment Advisers LLC raised its position in shares of Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after acquiring an additional 290 shares during the period. Intech Investment Management LLC raised its position in shares of Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after acquiring an additional 424 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after acquiring an additional 550 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $41.20 on Tuesday. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 52-week low of $19.07 and a 52-week high of $56.05. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -7.44 and a beta of 0.92. The business has a 50-day moving average price of $36.15 and a 200-day moving average price of $41.35.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the firm posted ($0.81) earnings per share. Equities analysts predict that Vera Therapeutics will post -6.23 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.